Background: Various reports have recently shown the efficacy of narrowband ultraviolet (UV) B phototherapy at 311 nm in the treatment of early stage mycosis fungoides (MF). Objectives: To examine the effectiveness and tolerability of monochromatic excimer light (MEL) at 308 nm as a first treatment for early stage MF (stage IA). Methods: Ten lesions from five patients with a clinical and histological diagnosis of MF were treated with repeated applications of MEL until complete remission was achieved or up to a maximum of 10 applications, with a cumulative dose of 308 nm UVB of between 6 and 12 J cm-2. All patients were observed every 2 weeks for 2 months, with a 1-year follow-up. Results: At present, all patients are in complete remission, with no side-effects. Conclusions: Based on these results, MEL can be considered a useful tool in the treatment of early stage MF.
Nistico', S.p., Costanzo, A., Saraceno, R., Chimenti, S. (2004). Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. BRITISH JOURNAL OF DERMATOLOGY, 151(4), 877-879 [10.1111/j.1365-2133.2004.06178.x].
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides
NISTICO', STEVEN PAUL;COSTANZO, ANTONIO;SARACENO, ROSITA;CHIMENTI, SERGIO
2004-01-01
Abstract
Background: Various reports have recently shown the efficacy of narrowband ultraviolet (UV) B phototherapy at 311 nm in the treatment of early stage mycosis fungoides (MF). Objectives: To examine the effectiveness and tolerability of monochromatic excimer light (MEL) at 308 nm as a first treatment for early stage MF (stage IA). Methods: Ten lesions from five patients with a clinical and histological diagnosis of MF were treated with repeated applications of MEL until complete remission was achieved or up to a maximum of 10 applications, with a cumulative dose of 308 nm UVB of between 6 and 12 J cm-2. All patients were observed every 2 weeks for 2 months, with a 1-year follow-up. Results: At present, all patients are in complete remission, with no side-effects. Conclusions: Based on these results, MEL can be considered a useful tool in the treatment of early stage MF.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.